U.S. Bioscience Hexalen agreement
Executive Summary
U.S. Bioscience signs agreement with Stockholm-based, Swedish Orphan AB involving the development and marketing of the anticancer agent Hexalen in Sweden, Norway, Denmark, Iceland and Finland. Hexalen is currently under development by U.S. Bioscience and is being studied in ovarian cancer.